

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#5
P. S. Buys
RECEIVED
JUN 24 2002

In re Application of:

Examiner: Hieu Phan

Wouter E. Roorda

Serial No.: 09/748,412

Art Unit: 3738

Filed: December 21, 2000

Title: Device And Active Component For Inhibiting Formation Of Thrombus –
Inflammatory Cell Matrix

TECHNOLOGY CENTER R9700

Commissioner for Patents
Washington, DC 20231

**INFORMATION DISCLOSURE STATEMENT PURSUANT
TO 37 C.F.R. §§1.97-1.98**

Dear Examiner Phan:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and pursuant to 37 C.F.R. §§1.97-1.98, Applicant hereby notifies the U.S. Patent and Trademark Office of the references listed on the attached Form PTO-1449. One copy of each cited reference is submitted herewith.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant reserves the right to dispute any of the listed documents as prior art during examination. Furthermore, Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application. The submission of this Information Disclosure Statement is not to be construed as a representation that a search has been made or that no other material information may exist.

06/19/2002 MGBREM1 00000014 071850 09748412

02 FC:126 180.00 CH


The Examiner is requested to initial the enclosed Form PTO-1449 and return a copy thereof to the undersigned.

The present Information Disclosure Statement is being submitted after receiving an Office Action and after three months of the filing date of the above-identified application. Therefore, please charge Deposit Account No. 07-1850 in the amount of \$180.00 as specified in 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p).

Date: June 10, 2002

Squire, Sanders & Dempsey L.L.P.
One Maritime Plaza, Suite 300
San Francisco, CA 94111
Telephone (415) 954-0200
Facsimile (415) 393-9887

Respectfully submitted,


Cameron K. Kerrigan
Attorney for Applicants
Reg. No. 44,826

FORM PTO-1449 (Modified)		US DEPARTMENT OF COMMERCE		Docket No. 50623.26		Application No. 09/748,122	
Approved for use through 10/31/2002		US Patent and Trademark Office		Applicant Wouter E. Roore		Filing Date December 21, 2000	
INFORMATION DISCLOSURE CITATION in an Application				Group Art Unit 3738			
(Use several sheets if necessary)				JUN 24 2002 TECHNOLOGY CENTER			
U.S. PATENT DOCUMENTS							
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
	A1	2,072,303	3/2/37	Herrmann et al.	128	335.5	
	A2	4,733,665	3/29/88	Palmaz	128	343	
	A3	4,800,882	1/31/89	Gianturco	128	343	
	A4	4,886,062	12/12/89	Wiktor	128	343	
	A5	4,931,287	6/5/90	Bae et al.	424	484	
	A6	4,977,901	12/18/90	Ofstead	128	772	
	A7	5,171,217	12/15/92	March et al.	604	53	
	A8	5,328,471	7/12/94	Slepian	604	101	
	A9	5,383,928	1/24/95	Scott et al.	623	1	
	A10	5,464,650	11/7/95	Berg et al.	427	2.30	
	A11	5,575,815	11/19/96	Slepian et al.	623	1	
	A12	5,578,073	11/26/96	Haimovich et al.	623	1	
	A13	5,605,696	2/25/97	Eury et al.	424	423	
	A14	5,628,730	5/13/97	Shapland et al.	604	21	
	A15	5,667,767	9/16/97	Greff et al.	424	9.411	
	A16	5,670,558	9/23/97	Onishi et al.	523	112	
	A17	5,700,286	12/23/97	Tartaglia et al.	623	1	
	A18	5,716,981	2/10/98	Hunter et al.	514	449	
	A19	5,780,044	7/14/98	Yewey et al.	424	426	
	A20	5,800,392	9/1/98	Racchini	604	96	
	A21	5,817,343	10/6/98	Burke	424	489	
	A22	5,824,049	10/20/98	Ragheb et al.	623	1	
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (Modified) Approved for use through 10/31/2002		US DEPARTMENT OF COMMERCE US Patent and Trademark Office		Docket No. 50623.26	Application No. 09/748,412		
INFORMATION DISCLOSURE CITATION in an Application				Applicant Wouter E. Roorda			
(Use several sheets if necessary)				Filing Date December 21, 2000		Group Art Unit 3738	
U.S. PATENT DOCUMENTS							
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
	A23	5,830,178	11/3/98	Jones et al.	604	49	
	A24	5,837,008	11/17/98	Berg et al.	623	1	
	A25	5,837,313	11/17/98	Ding et al.	427	2.21	
	A26	5,851,231	12/22/98	Wolff et al.	623	1	
	A27	5,851,508	12/22/98	Greff et al.	424	9.411	
	A28	5,865,814	2/2/99	Tuch	604	265	
	A29	5,869,103	2/9/99	Yeh et al.	424	501	
	A30	5,873,904	2/23/99	Ragheb et al.	623	1	
	A31	5,951,586	9/14/99	Berg et al.	606	198	
	A32	5,971,954	10/26/99	Conway et al.	604	96	
	A33	5,980,928	11/9/99	Terry	424	427	
	A34	5,980,972	11/9/99	Ding	427	2.24	
	A35	5,981,719	11/9/99	Woiszwilllo et al.	530	410	
	A36	6,010,530	1/4/00	Goicoechea	623	1	
	A37	6,015,541	1/18/00	Greff et al.	424	1.25	
	A38	6,096,070	8/1/00	Ragheb et al.	623	1	
	A39	6,110,483	8/29/00	Whitbourne et al.	424	423	
	A40	6,153,252	11/28/00	Hossainy et al.	427	2.3	
	A41	6,165,212	12/26/00	Dereume et al.	623	1.13	
	A42	6,214,901	4/10/01	Chudzik et al.	523	113	
	A43	6,262,034	7/17/01	Mathiowitz et al.	514	44	
	A44	6,263,880	7/24/01	Parker et al.	128	898	
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (Modified) Approved for use through 10/31/2002		US DEPARTMENT OF COMMERCE US Patent and Trademark Office		Docket No. 50623.26		Application No. 09/748,412		
INFORMATION DISCLOSURE CITATION in an Application				Applicant Wouter E. Roorda				
(Use several sheets if necessary)				Filing Date December 21, 2000		Group Art Unit 3738		
FOREIGN PATENT DOCUMENTS								
Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation	
							Yes	No
	B1	EP 0665023	8/2/95	European				
	B2	EP 0970711	1/12/00	European				
	B3	WO 91/12846	9/5/91	PCT				
	B4	WO 95/24929	9/21/95	PCT				
	B5	WO 97/45105	12/4/97	PCT				
	B6	WO 99/63981	12/16/99	PCT				
	B7	WO 00/12147	3/9/00	PCT				
	B8	WO 00/64506	11/2/00	PCT				
	B9	WO 01/01890	1/11/01	PCT				
	B10	WO 01/45763	6/28/01	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)								
	C1	Barath et al., <i>Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury</i> , JACC 13(2):252A (1989).						
	C2	Komatsu et al., <i>Neointimal Tissue Response at Sites of Coronary Stenting in Humans, Macroscopic, Histological, and Immunohistochemical Analyses</i> , Circulation, 98:224-233 (1998).						
	C3	Matsumaru et al., <i>Embolic Materials for Endovascular Treatment of Cerebral Lesions</i> , J. Biomater. Sci. Polymer Edn. 8(7):555-569 (1997).						
	C4	Miyazaki et al., <i>Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice</i> , Chem. Pharm. Bull. 33(6):2490-2498 (1985).						
	C5	Miyazawa et al., <i>Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat</i> , J. Cardiovasc. Pharmacol. 30(2):157-162 (1997).						
	C6	Ohsawa et al., <i>Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty</i> , Am. Heart J. 136(6):1081-1087 (1998).						
	C7	Shigeno, <i>Prevention of Cerebrovascular Spasm by Bosentan, Novel Endothelin Receptor</i> , Chem. Abstracts 125:212307 (1996).						
EXAMINER				DATE CONSIDERED				
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								